CIM
AIMT

CIM Investment Management’s Aimmune Therapeutics AIMT Stock Holding History

CIM Investment Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,967
Closed -$274K – 309
2020
Q3 		$274K Sell
7,967
-12,971
-62% -$276K 0.1% 183
2020
Q2 		$350K Buy
20,938
+6,169
+42% +$105K 0.14% 142
2020
Q1 		$213K Buy
+14,769
New +$377K 0.1% 159

CIM Investment Management's AIMT Position: Q4 2020 in Review

CIM Investment Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 7,967 shares — an estimated $274K sold.

CIM Investment Management first reported a position in AIMT in Q1 2020 and held it in 3 quarters. The position peaked at $350K in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • CIM Investment Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CIM Investment Management sold 7,967 Aimmune Therapeutics shares in Q4 2020, an estimated $274K.
  • CIM Investment Management first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 3 quarters.
  • CIM Investment Management's Aimmune Therapeutics position peaked at $350K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on CIM Investment Management's 13F filing for Q4 2020, filed 17 Feb 2021.